HEALWELL is an AI healthcare leader, Haywood says

Healwell AI (Healwell AI Stock Quote, Chart, News, Analysts, Financials TSXV:AIDX) has made “significant progress” in its core AI business and acquired full ownership of Pentavere, according to Haywood Capital Markets analyst Gianluca Tucci, who maintained a “Buy” rating and $4.50 price target in a July 16 update.

Toronto-based Healwell AI is a healthcare technology company that uses artificial intelligence to help doctors detect complex and chronic diseases earlier. Its tools are used across clinics in Canada, with growing expansion into the U.S. market.

Healwell’s AI business is on track to bring in over $5 million in revenue for the first half of 2025, more than triple what it made during the same period last year.

“This strong performance is expected to lead to positive Adjusted EBITDA for the AI segment during the same period,” Tucci said. “This indicates strong operational leverage and potential profitability for its AI ventures. Both Pentavere and Khure Health, key components of the AI segment, saw over 100% growth in the first half of 2025 compared to the same period last year. This highlights its increasing market penetration and strong demand for its AI solutions.”

Tucci said the company has now taken full ownership of Pentavere, a well-known AI healthcare company, by exercising its option to buy the remaining 49% it didn’t already own. The $14-million deal was completed through the issuance of 10.2 million shares at $1.38 each.

“Pentavere is the developer of DARWEN, a leading AI-driven patient identification platform,” he said. “This full ownership allows for deeper integration and accelerated commercialization of its AI products. We view these updates as positive and showing early signs of successful synergies between AIDX and its recently acquired Orion Health. Healwell AI is demonstrating robust growth in its core AI business, driven by strong organic performance and the strategic consolidation of Pentavere.”

Tucci said Healwell is in a strong position to benefit from the growing demand for AI-powered preventative care. He called it a compelling opportunity for investors seeking exposure to fast-growing healthcare tech. Full results for Q2 2025 are expected in August.

“With a core focus on preventative care and early disease detection, Healwell isn’t just riding the wave – it’s actively shaping it,” he said. “Through its proprietary AI clinical co-pilot tools, the company is empowering healthcare providers to detect rare and chronic diseases earlier, a critical step towards improving patient outcomes and reducing systemic healthcare costs. This proactive approach directly addresses the growing demand for solutions that move beyond reactive treatment to truly predictive and preventative health management.”

Tucci expects Healwell to post $4.1-million in Adjusted EBITDA on $136-million in revenue in 2025, rising to $18.5-million in EBITDA and $190.9-million in revenue in 2026.

“I’m incredibly pleased with the strong performance of our core AI division, and I believe its potential is substantial,” James Lee, Healwell’s new CEO as of July 1, said in a company update on July 16. “With Orion Health now part of our family and 100% ownership of Pentavere, we have a unique opportunity to truly differentiate our offering and accelerate the commercialization of our AI products. We are already seeing strong interest in our various AI products, from some of the largest healthcare systems in the world.”

Disclosure: Nick Waddell owns shares of AIDX

-30-